Subsequently, we used the RXLD-related GBM targets’ network, the PPI network, and the KEGG network for further screening, and we eventually identified some core targets of RXLD for the treatment of GBM (such as HRAS, PRKCB, MAPK9, CCND1, TP53, etc.). Here, MAPK9 is linked to glioblastoma.